Abstract Library

#4295 Are patients on somatostatin analogue therapy receiving high quality holistic cancer nursing care?

Introduction: SSA is indicated for the treatment of G1 and some G2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin in adult patients with unresectable locally advanced or metastatic disease. As these types of cancer have much lower proliferation rates than common cancers, they are not exclusively considered cancer. It is hypothesised these patients may subsequently receive sub-standard cancer care. Furthermore, patients who are diagnosed with metastatic G3 neuroendocrine cancers will require systemic treatment with significant side effect profiles impacting negatively on quality of life.

Conference:

Presenting Author:

Authors: Wotherspoon I,

Keywords: Cancer nursing,

#4252 Intra-arterial Peptide Receptor Radionuclide Therapy in a Filipino male with predominantly hepatic metastasis in a known primary pancreatic neuroendocrine tumor

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has shown positive clinical outcomes in somatostatin receptor (SSTR) overexpressing positive well-differentiated neuroendocrine tumors in combination with somatostatin analogue therapy. A noted decreased progression-free survivability in the use of PRRT has been noted in larger lesions (>3cm).

Conference:

Presenting Author: Azarraga C

Authors: Azarraga C, Leogardo D, Bandong I, Bautista-Peñalosa P,

Keywords: neuroendocrine, PRRT, intra-arterial, bulky,

#4144 Phase Ib portion of the ACTION-1 Phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings

Introduction: RYZ101 (225Ac-DOTATATE) is an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors.

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Ulaner G, Halperin D, Mehr S, Kotiah S,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Somatostatin analogue therapy, Somatostatin receptor positive, RYZ101,

#4132 ACTION-1: A randomised phase Ib/3 trial of RYZ101 compared with standard of care in somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors with progression following 177Lu somatostatin analogue therapy

Introduction: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by high-density expression of somatostatin receptors (SSTRs). RYZ101 (225Ac-DOTATATE) is a highly potent alpha-emitting radiopharmaceutical therapy (RPT) being developed for SSTR+ solid tumors. ACTION-1 is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial of RYZ101. Part 1 (Phase 1b), an uncontrolled dose de-escalation study, is complete with no dose-limiting toxicities.

Conference:

Presenting Author: Singh S

Authors: Singh S, Tesselaar M, Strosberg J, Jacene H, Halperin D,

Keywords: RYZ101, Gastroenteropancreatic neuroendocrine tumor, Somatostatin receptor, Radiopharmaceutical therapy,

#3920 Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary

Introduction: The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel approaches in the management of neuroendocrine tumors (NETs).

Conference:

Presenting Author: Chianpian C

Authors: Chianpian C, Bautista-Peñalosa P, Santos C, Bandong I,

Keywords: peptide receptor radionuclide therapy, metastatic pancreatic neuroendocrine tumor, Ga-68 DOTATATE, Lu-177 DOTATATE, Philippines,